Neo Ivy Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Neo Ivy Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-257	Closed	-$19K	–	605
2022 Q2	$19K	Buy	+257	New	+$11.4K	0.05%	315
2021 Q3	–	Sell	-372	Closed	-$29K	–	680
2021 Q2	$29K	Buy	+372	New	+$27.5K	0.03%	358

Neo Ivy Capital Management's TPTX Position: Q3 2022 in Review

Neo Ivy Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 257 shares — an estimated $19K sold.

Neo Ivy Capital Management first reported a position in TPTX in Q2 2021 and held it in 2 quarters. The position peaked at $29K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Neo Ivy Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 257 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $19K.
Neo Ivy Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
Neo Ivy Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $29K in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Neo Ivy Capital Management's 13F filing for Q3 2022, filed 16 Nov 2022.